US20150054195A1 - Method for 3-D Printing a Custom Bone Graft - Google Patents
Method for 3-D Printing a Custom Bone Graft Download PDFInfo
- Publication number
- US20150054195A1 US20150054195A1 US14/447,085 US201414447085A US2015054195A1 US 20150054195 A1 US20150054195 A1 US 20150054195A1 US 201414447085 A US201414447085 A US 201414447085A US 2015054195 A1 US2015054195 A1 US 2015054195A1
- Authority
- US
- United States
- Prior art keywords
- bone
- graft
- ink
- porous
- custom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 151
- 238000000034 method Methods 0.000 title claims description 52
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims abstract description 42
- 239000004926 polymethyl methacrylate Substances 0.000 claims abstract description 42
- 239000002243 precursor Substances 0.000 claims abstract description 21
- 239000007788 liquid Substances 0.000 claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 15
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 239000013078 crystal Substances 0.000 claims abstract description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 11
- 229930006000 Sucrose Natural products 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 239000005720 sucrose Substances 0.000 claims abstract description 11
- 230000004819 osteoinduction Effects 0.000 claims abstract description 10
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 7
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 34
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 34
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 33
- 239000000560 biocompatible material Substances 0.000 claims description 17
- 210000002805 bone matrix Anatomy 0.000 claims description 17
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 12
- 230000003115 biocidal effect Effects 0.000 claims description 11
- 102000008186 Collagen Human genes 0.000 claims description 10
- 108010035532 Collagen Proteins 0.000 claims description 10
- 229920001436 collagen Polymers 0.000 claims description 10
- 239000004568 cement Substances 0.000 claims description 9
- 238000003384 imaging method Methods 0.000 claims description 9
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 8
- 229920002301 cellulose acetate Polymers 0.000 claims description 8
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 8
- 239000007870 radical polymerization initiator Substances 0.000 claims description 8
- 108010023714 recombinant human bone morphogenetic protein-2 Proteins 0.000 claims description 8
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 7
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 7
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 5
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 5
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- MCMNRKCIXSYSNV-UHFFFAOYSA-N ZrO2 Inorganic materials O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims description 4
- 229960003722 doxycycline Drugs 0.000 claims description 4
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 claims description 4
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229930182566 Gentamicin Natural products 0.000 claims description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229960002518 gentamicin Drugs 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003022 amoxicillin Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000005477 standard model Effects 0.000 claims description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 27
- 239000004615 ingredient Substances 0.000 abstract description 8
- 229940088710 antibiotic agent Drugs 0.000 abstract description 3
- 230000002138 osteoinductive effect Effects 0.000 abstract description 2
- 239000003505 polymerization initiator Substances 0.000 abstract 1
- 239000000976 ink Substances 0.000 description 30
- 238000005094 computer simulation Methods 0.000 description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 description 11
- 238000003754 machining Methods 0.000 description 11
- 238000001356 surgical procedure Methods 0.000 description 11
- 239000011159 matrix material Substances 0.000 description 10
- 230000007547 defect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000002787 reinforcement Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000002639 bone cement Substances 0.000 description 7
- -1 but not limited to Chemical class 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 230000000399 orthopedic effect Effects 0.000 description 5
- 230000003239 periodontal effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 238000003801 milling Methods 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004513 dentition Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000036346 tooth eruption Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 239000000316 bone substitute Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000011507 gypsum plaster Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- 208000020564 Eye injury Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940038195 amoxicillin / clavulanate Drugs 0.000 description 1
- 229940043312 ampicillin / sulbactam Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012227 artificial bone substitute Substances 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000005313 bioactive glass Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000004068 calcium phosphate ceramic Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- NWOYIVRVSJDTLK-YSDBFZIDSA-L disodium;(2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylate Chemical compound [Na+].[Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 NWOYIVRVSJDTLK-YSDBFZIDSA-L 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003178 glass ionomer cement Substances 0.000 description 1
- 239000011440 grout Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 239000012705 liquid precursor Substances 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000000278 osteoconductive effect Effects 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940104641 piperacillin / tazobactam Drugs 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 1
- 229960003053 thiamphenicol Drugs 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- B29C67/0081—
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F30/00—Computer-aided design [CAD]
- G06F30/20—Design optimisation, verification or simulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2/30942—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
- B29C64/10—Processes of additive manufacturing
- B29C64/165—Processes of additive manufacturing using a combination of solid and fluid materials, e.g. a powder selectively bound by a liquid binder, catalyst, inhibitor or energy absorber
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
-
- G—PHYSICS
- G05—CONTROLLING; REGULATING
- G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
- G05B19/00—Programme-control systems
- G05B19/02—Programme-control systems electric
- G05B19/18—Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of programme data in numerical form
- G05B19/4097—Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of programme data in numerical form characterised by using design data to control NC machines, e.g. CAD/CAM
- G05B19/4099—Surface or curve machining, making 3D objects, e.g. desktop manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2825—Femur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2853—Humerus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2002/3092—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth having an open-celled or open-pored structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2/30942—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques
- A61F2002/30948—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques using computerized tomography, i.e. CT scans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2/30942—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques
- A61F2002/30952—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques using CAD-CAM techniques or NC-techniques
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2/30942—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques
- A61F2002/30957—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques using a positive or a negative model, e.g. moulds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2/30942—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques
- A61F2002/30962—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques using stereolithography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2002/30971—Laminates, i.e. layered products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
- A61F2240/002—Designing or making customized prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00353—Bone cement, e.g. polymethylmethacrylate or PMMA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00359—Bone or bony tissue
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/02—Small extruding apparatus, e.g. handheld, toy or laboratory extruders
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/25—Component parts, details or accessories; Auxiliary operations
- B29C48/266—Means for allowing relative movements between the apparatus parts, e.g. for twisting the extruded article or for moving the die along a surface to be coated
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2001/00—Use of cellulose, modified cellulose or cellulose derivatives, e.g. viscose, as moulding material
- B29K2001/08—Cellulose derivatives
- B29K2001/12—Cellulose acetate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2029/00—Use of polyvinylalcohols, polyvinylethers, polyvinylaldehydes, polyvinylketones or polyvinylketals or derivatives thereof as moulding material
- B29K2029/04—PVOH, i.e. polyvinyl alcohol
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2033/00—Use of polymers of unsaturated acids or derivatives thereof as moulding material
- B29K2033/04—Polymers of esters
- B29K2033/12—Polymers of methacrylic acid esters, e.g. PMMA, i.e. polymethylmethacrylate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2039/00—Use of polymers with unsaturated aliphatic radicals and with a nitrogen or a heterocyclic ring containing nitrogen in a side chain or derivatives thereof as moulding material
- B29K2039/06—Polymers of N-vinyl-pyrrolidones
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2067/00—Use of polyesters or derivatives thereof, as moulding material
- B29K2067/04—Polyesters derived from hydroxycarboxylic acids
- B29K2067/046—PLA, i.e. polylactic acid or polylactide
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
- B29K2105/0011—Biocides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
- B29K2105/0014—Catalysts
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
- B29K2105/0035—Medical or pharmaceutical agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0088—Blends of polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/04—Condition, form or state of moulded material or of the material to be shaped cellular or porous
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
- B29K2995/0037—Other properties
- B29K2995/0056—Biocompatible, e.g. biopolymers or bioelastomers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
- B29K2995/0037—Other properties
- B29K2995/0059—Degradable
- B29K2995/006—Bio-degradable, e.g. bioabsorbable, bioresorbable or bioerodible
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/753—Medical equipment; Accessories therefor
- B29L2031/7532—Artificial members, protheses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y10/00—Processes of additive manufacturing
-
- G—PHYSICS
- G05—CONTROLLING; REGULATING
- G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
- G05B2219/00—Program-control systems
- G05B2219/30—Nc systems
- G05B2219/45—Nc applications
- G05B2219/45168—Bone prosthesis
-
- G—PHYSICS
- G05—CONTROLLING; REGULATING
- G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
- G05B2219/00—Program-control systems
- G05B2219/30—Nc systems
- G05B2219/49—Nc machine tool, till multiple
- G05B2219/49023—3-D printing, layer of powder, add drops of binder in layer, new powder
Definitions
- the invention relates to producing a custom bone graft, and more particularly to methods of producing custom bone grafts using 3-D printing and/or CNC machining, or a combination thereof.
- Bone grafting is possible because bone tissue, unlike most other tissues, has the ability to regenerate completely if provided the right environment, including a space into which to grow, or a matrix to grow on. As native bone grows, it replaces the graft material, so that over time, the graft is replaced by a fully integrated region of new bone.
- Bone regeneration occurs through osteoinduction, a process in which connective tissue is converted into bone by an appropriate stimulus. Osteoinduction allows bone formation to be induced even at non-skeletal sites and is initiated by bone morphogenetic proteins (BMP).
- BMP bone morphogenetic proteins
- the ideal bone graft material would be a strong, porous biocompatible material infused with BMP that did not cause inflammation and would ultimately be reabsorbed into the body as it is replaced by natural bone.
- Bone is composed of 50 to 70% inorganic mineral, 20 to 40% organic collagen matrix, 5 to 10% water, and ⁇ 3% lipids.
- the inorganic mineral content of bone is mostly hydroxyapatite [Ca 10 (PO 4 )6(OH) 2 ].
- the inorganic mineral provides the mechanical strength and rigidity, whereas the organic collagen matrix provides elasticity and flexibility.
- Demineralized bone matrix is allograft bone, i.e., bone from other humans, that has had the inorganic, mineral material removed, leaving behind the organic collagen matrix and the BMPs that induce osteoinduction.
- DBM is conducive to osteoinduction, but lacks the load bearing strength. It is typically used with a 2-4% hyaluronate carrier as a paste or putty to fill a space needing bone, and allows real bone to grow into it within weeks to months.
- the present invention provides a system and method of producing custom bone grafts that are made of a porous, biocompatible material infused with BMPs that can be used as ink in a 3-D printer to produce bone grafts of any desired shape.
- special supporting devices that include pre-fabricated features common between certain parts are used in order to facilitate the machining process.
- the identification of key-points is done by comparing a schematic drawing of the type of part being replaced to the actual part. A grid is then used to measure the coordinates for those key-points.
- U.S. Pat. No. 6,671,539 issued to Gateno et al. on Dec. 30, 2003 entitled “Method and apparatus for fabricating orthogenetic surgical splints” that describes a method of forming a surgical splint to receive a patient's dentition and thereby align the upper jaw and the lower jaw during surgery includes generating a CT computer model of bone structure, generating a digital dental computer model of the patient's dentition, and then combining the CT computer model and the digital dental computer model to form a composite computer model.
- the composite computer model may be displayed, and at least one of the upper jaw and lower jaw repositioned relative to the patient's skull and the composite computer model to form a planned position computer model.
- a computer model surgical splint of the patient's dentition may be formed, which is then input into a fabrication machine to form a surgical splint.
- the method also includes forming and displaying the composite computer model.
- a workstation includes a CT machine, a digital scanner, a computer, an input command mechanism, a display, and a fabricating machine.
- a method for creating a data record which can be used for a rapid prototyping method for manufacturing a dental prosthesis wherein an end data record is obtained from a starting data record, so that in at least one area of a dental prosthesis manufactured with the end data record excess material is provided, compared to a dental prosthesis manufactured with the starting data record.
- the present invention describes systems and methods for producing a custom bone graft.
- a 3-D image of an intended graft location may be obtained. This may be achieved by a number of methods, some of which may be discussed in further detail later.
- Use may, for instance, be made of 3-D image construction techniques such as, but not limited to, obtaining multiple 2-D X-ray images at different orientations, and using computational techniques to convert these into a 3-D image, using a Cone beam imaging device or a cat-scan device, or some combination thereof.
- This 3-D image of the graft location may then be converted into a 3-D digital image of the custom bone graft.
- the custom bone graft may be printed directly using a modified 3-D printer and an ink that transforms into a suitable porous, biocompatible, biodegradable material that is conducive to osteoinduction and has a load bearing strength comparable to bone.
- the custom bone graft may also or instead be made by using a 3-D printer to print a negative form or mold, and the mold may then be used to produce the custom bone graft.
- the mold may be filled with a mixture of, for instance, Calcium Sulfate hemihydrate, aka Plaster of Paris, demineralized freeze dried bone (DFDB), or freeze dried bone (FDB), Bone Morphogenetic Proteins (BMP) and an antibiotic such as, but not limited to, Doxycycline.
- the porous, biocompatible material may be porous Poly Methyl Methacrylate (PMMA) and demineralized allograft bone matrix (DMB).
- the ink for this material may, for instance, be provided as a precursor powder, and a precursor liquid.
- the precursor powder may, for instance, include demineralized allograft bone matrix (DMB), sucrose crystals and a radical polymerization initiator.
- the precursor liquid may, for instance, include Methyl Methacrylate (MMA) as well as one or more antibiotics and one or more radio-pacifiers, i.e., compounds that make the graft more radio opaque, or radio dense, so that it may be more visible on X-ray images.
- the radical polymerization initiator may be benzoyl peroxide
- the antibiotic may be gentamicin
- the radio-pacifier may be barium sulphate.
- the precursor liquid and powder may be mixed in small batches to produce the ink just before printing. Once the precursors are mixed the MMA may start to polymerize to PMMA.
- the viscosity of the liquid will increase with time, but suitably proportioned, the ink may be delivered through a 10-14 gauge needle or print nozzle for about 10 to 20 minutes. This may provide a dot size of about 2 mm in diameter, which may be the resolution of the finest detail of the custom bone graft.
- sucrose crystals provide the porosity to the structure when they are dissolved out in post print processing.
- the structure printed by the ink may also be made biodegradable by the inclusion of cellulose acetate (CA) or cellulose acetate phthalate (CAP), or a combination thereof.
- the biodegradability may allow the porous PMMA structure to be replaced by natural bone over time.
- FIG. 1 shows a preferred embodiment of a method for producing a custom bone graft.
- FIG. 2 shows a magnified section of the mineral structure of bone.
- FIG. 3 shows a magnified section of a demineralized allograft bone matrix (DMB).
- DMB demineralized allograft bone matrix
- FIG. 4 shows a magnified section of a porous, biocompatible material suitable for use as a bone graft.
- FIG. 5 shows a magnified section of an intermediate stage in producing porous Poly Methyl Methacrylate (PMMA).
- PMMA Poly Methyl Methacrylate
- FIG. 6 shows a sematic layout of the ink mixing and print nozzle of a preferred embodiment of the present invention.
- FIG. 7 shows a sematic flow diagram of representative steps of a preferred embodiment of the present invention.
- FIG. 8 shows a cone-beam scan of a patient used by computer software to produce an image of a bone defect.
- FIG. 9 shows a sectional view of a 3-D reconstruction of an imaged defect.
- FIG. 10 shows a sectional view of a computer generated 3-D positive image of a required graft.
- FIG. 11 shows a sectional view of a negative mold of a required graft.
- FIG. 12 shows a sectional view of a negative mold being used to produce a required graft.
- FIG. 13 shows a sectional view of a graft being placed during surgery.
- FIG. 14 A shows a required complex long bone graft.
- FIG. 14 B shows a negative mold for a portion of the required complex long bone graft.
- FIG. 14 C shows a negative mold being used to produce a portion of the required complex long bone graft.
- FIG. 14 D shows a negative mold being used to produce a portion of the required complex long bone graft.
- FIG. 1 shows a preferred embodiment of a method for producing a custom bone graft.
- An X-ray imaging machine 155 may be used to take one or more images of a region of a patent where a custom bone graft 120 may be needed. These may then be assembled into a 3-D image 105 of the region requiring a custom bone graft 120 .
- a suitably programmed digital processor 240 may take the 3-D image 105 and transform it into a 3-D model of the region requiring the custom bone graft 120 . This 3-D model may then be used to generate a 3-D model of the required custom bone graft 120 .
- This 3-D model of the required custom bone graft 120 may then be used by a software module operative on the digital processor 240 to generate instructions for a 3-D printer 115 .
- These instructions may, for instance, take the form of a 3-D digital model 110 made up of a series of layers 245 .
- These layers of a 3-D digital model 245 may, for instance, be sized to the resolution of the 3-D printer 115 that may be used to generate the custom bone graft 120 .
- a 3-D printer 115 may then be used to produce the custom bone graft 120 layer by layer using an appropriate ink, or series of inks.
- the X-ray imaging machine 155 may be a Cone Beam 3 D camera such as, but not limited to, the model GX DP-700 supplied by Gendex Dental Systems of Hatfield, Pa.
- other imaging devices may be used such as, but not limited to, other computer aided tomography devices, cat-scan devices, 3-D laser cameras or a combination thereof.
- FIG. 2 shows a magnified section of the mineral structure of bone.
- Mammalian bone may be composed of a bone mineral 215 having a lattice or matrix of voids 220 .
- Bone may typically be composed of 50 to 70% inorganic mineral, 20 to 40% organic collagen matrix, 5 to 10% water, and ⁇ 3% lipids.
- the organic collagen, water, lipids and blood vessels are typically contained within the voids.
- the inorganic mineral content of bone is mostly hydroxyapatite [Ca 10 (PO 4 ) 6 (OH) 2 ].
- the inorganic mineral provides the mechanical strength and rigidity, whereas the organic collagen matrix provides elasticity and flexibility.
- FIG. 3 shows a magnified section of a demineralized allograft bone matrix (DMB).
- the demineralized allograft bone matrix (DMB) 145 may be made up of collagen 130 , typically formed into a matrix structure, and bone morphogenetic proteins (BMP) 135 .
- Bone morphogenetic proteins (BMPs) are a group of growth factors also known as cytokines and as metabolomes. They were originally discovered through their ability to induce the formation of bone and cartilage, and are now considered to constitute a pivotal group of morphogenetic signals that may orchestrate tissue architecture throughout the body.
- demineralized allograft bone matrix (DMB) 145 is a favored source, and may be used in a paste or putty to facilitate bone regeneration.
- Demineralized allograft bone matrix (DMB) 145 i.e., allograft bone that has had inorganic minerals removed, may expose more bone morphogenetic proteins (BMP) 135 and therefore facilitate faster growth of natural bone into the paste or putty.
- Demineralized allograft bone matrix (DMB) 145 does not, however, have the strength of natural bone. Allograft bone is human bone, typically taken from cadavers and bone banks.
- Demineralized allograft bone (DMB) 145 may be obtained from, for instance, MAXXEUS Inc., of Kettering, Ohio who sells it under the brand name MAXXEUSTM DBM PUTTY.
- FIG. 4 shows a magnified section of a porous, biocompatible material suitable for use as a bone graft.
- the porous, biocompatible material 125 may, for instance, be made up of a biocompatible, porous structural support 250 made conducive to osteoinduction by the presence of bone morphogenetic proteins (BMP) 135 .
- BMP bone morphogenetic proteins
- the biocompatible, porous structural support 250 may, for instance, be porous Poly Methyl Methacrylate (PMMA) 140 and the bone morphogenetic proteins (BMP) 135 may, for instance, be demineralized allograft bone matrix (DBM) 145 .
- the bone morphogenetic proteins (BMP) 135 may also, or instead, be a synthetically produced compound such as, but not limited to, recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) as provided by, for instance, Medtronic Inc. of Minneapolis, Minn. in their INFUSE Bone Graft material.
- Poly Methyl Methacrylate (PMMA) 140 is a synthetic polymer of methyl methacrylate, whose biocompatibility was, apparently, discovered by accident during military when RAF pilots suffered eye injuries from the destruction of their side widows. Hawker Hurricane pilots, whose windows were made of glass, suffered severe rejection/infection in the vicinity of the glass splinters in their eyes, while Spitfire pilots, whose side windows were made of PMMA suffered no rejection/infection in the vicinity of the PMMA splinters. This good degree of compatibility with human tissue has been exploited by using PMMA for intraocular eye lenses that replace cataract damaged lenses, and in orthopedic surgery. In orthopedic surgery it is used as a grout, or bone cement, to stabilize join implants.
- PMMA bone cement such as, but not limited to, SIMPLEX PTM BONE CEMENT sold by the Stryker Corporation of Kalamazoo, Mich. is typically supplied as a powder and a liquid.
- the ingredients of Stryker's SIMPLEX PTM BONECEMENT are reported to be 75% methyl methacrylate; 15% polymethylmethacrylate (PMMA); 10% Barium Sulfate for radio-opaqueness, and an undisclosed quantity of benzoyl peroxide to initiate the radical induced polymerization of the MMA to PMMA.
- the amount of the radical polymerization initiator, benzoyl peroxide may be crucial for determining the mixing, handling, and setting characteristics of the bone cement.
- the powder and liquid precursors are mixed about 10 minutes before being used. Mixing the powder and liquid initiates the polymerization, which may take up to several hours to complete. They are either applied as putty, or delivered to the required site by means of needles that range in size from 10 to 14 gauges, i.e., in the vicinity of 2 mm internal bore needles.
- FIG. 5 shows a magnified section of an intermediate stage in producing porous poly methyl methacrylate (PMMA).
- the porous Poly Methyl Methacrylate (PMMA) 140 may be produced by including sucrose crystals 170 of the appropriate size in the MMA being polymerized. After the MMA is fully polymerized from its liquid form to solid form, the sucrose crystals 170 may be dissolved out, leaving behind a porous PMMA structure.
- PMMA bone cement Shortcomings of PMMA bone cement include that it heats up to 82.5° C. (160.5° F.) while setting. This is high enough to cause thermal necrosis of neighboring tissue, or any biomaterial such as, but not limited to, collagen and bone morphogenetic proteins (BMP) that may be found in demineralized allograft bone matrix (DMB).
- BMP bone morphogenetic proteins
- Porous cement may be obtained provided that a critical minimum percentage loading of the filler is exceeded so that the filler crystals will make physical contact with each other. The value of this percentage depends on both crystal modification and size. With crystals in the 125-175 micron range, the critical minimum percentage may be in the range of 20-28 wt. % loading. Above 30%, the interconnecting pore size increases and may allow good tissue ingrowth into the pores. The introduction of filler and pores may cause a drop in strength, but the tensile strength of modified cement containing up to 40% pores and sucrose lies between 0.7 and 1.5 kg/mm 2 ′, which is in the same range as that of bone.
- Poly methyl methacrylate may be made biodegradable by the addition of cellulose acetate (CA) 255 or cellulose acetate phthalate (CAP) 260 , as described in, for instance, an article by D. Batt et al. entitled “Biodegradability of PMMA Blends with Some Cellulose Derivatives”, published in Journal of Polymers and the Environment, October 2006, Volume 14, Issue 4, pp. 385-392, the contents of which are hereby incorporated by reference.
- CA cellulose acetate
- CAP cellulose acetate phthalate
- the rate of biodegradation may be controlled by the relative amount of the compound use to increase the biodegradability of the ink, or the product produced by the polymerized ink.
- FIG. 6 shows a sematic layout of an ink mixing and print nozzle of a preferred embodiment of the present invention.
- the ink may contain structural material ingredients; ingredients to form a porous, resorbable, matrix; and additives such as, but not limited to, synthetic BMPs, antibiotic chemicals, anti-inflammatory chemicals and radiopaque chemicals, or some combination thereof.
- the structural material ingredients may, for instance, include a substance such as, but not limited to, Hydroxyapatite, allograft particulate bone, xenograft particulate bone or some combination thereof.
- the ingredients to form a porous, resorbable matrix may include substances such as, but not limited to, methyl methacrylate, cellulose, resorbable cements, or precursors to resorbable cements or some combination thereof.
- Antibiotic additives may include any suitable antibiotic, or antibiotic combinations, such as, but not limited to, demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline, thiamphenicol, ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, nalidixic acid, norfloxacin, ofloxacin, bacitracin, colistin, amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin/tazobactam, ticarcillin/clavulanate, or some combination thereof.
- demeclocycline doxycycline, minocycline, oxytetracycline, tetracycline, thiamphenicol, ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin
- the ink may, for instance, be supplied in the form of a precursor powder 190 and a precursor liquid 195 . These may be feed to separate containers in the 3-D printer. Prior to printing, a quantity of the precursor powder 190 and the precursor liquid 195 may be mixed to form the ink 150 to be used for printing the custom bone graft 120 . The printing may be accomplished by delivering quantities of the ink 150 via a suitably sized print nozzle 235 that may be moved in a raster scan 230 with respect to the custom bone graft 120 being printed.
- the precursor powder 190 of the ink 150 may, for instance, contain a variety of ingredients such as, but not limited to, demineralized allograft bone matrix (DMB) 145 , sucrose crystals 170 , radical polymerization initiator 175 or some combination thereof.
- DMB demineralized allograft bone matrix
- the radical polymerization initiator 175 may, for instance, be a compound such as, but not limited to, di-benzoyl peroxide (BPO).
- BPO di-benzoyl peroxide
- the precursor liquid 195 may for, instance, contain a variety of ingredients such as, but not limited to, methyl methacrylate (MMA) 165 , a radio-pacifier 185 , an antibiotic 180 , and a compound to increase the biodegradability 265 , or some combination thereof.
- MMA methyl methacrylate
- radio-pacifier 185 an antibiotic 180
- a compound to increase the biodegradability 265 or some combination thereof.
- the radio-pacifier 185 may, for instance, be a compound such as, but not limited to, zirconium dioxide (ZrO 2 ) or barium sulphate (BaSO 4 ) or some combination thereof.
- the antibiotic 180 may, for instance, be a compound such as, but not limited to, amoxicillin, doxycycline, gentamicin or clindamycin or some combination thereof.
- the compound to increase the biodegradability 265 may, for instance, be a compound such as, but not limited to, cellulose acetate (CA), or cellulose acetate phthalate (CAP) or some combination thereof.
- CA cellulose acetate
- CAP cellulose acetate phthalate
- FIG. 7 shows a sematic flow diagram of representative steps of a preferred embodiment of the present invention.
- Step 701 “Obtain 3-D Image of Graft Location”
- the patient may be imaged using one of a number of well-known techniques for obtaining a 3-D image such as, but not limited to, a cone beam 3-D camera, computer aided tomography, 3-D laser cameras or a combination thereof.
- Step 702 “Create 3-D Model of Custom Bone Graft”
- the images obtained in step 701 may be used by a suitably constructed computer program operable on a suitable digital data processor, to generate a 3-D model of a custom bone graft for the patient.
- the computer program may also use a database of standard models of human body parts to provide guidance on areas that may not be adequately described or detailed by the 3-D images.
- the custom bone graft may also include provision for locating fixation screws that might be added using guidance from a qualified professional.
- Fixation screws including their size, location and orientation may be designed on the computer model by a competent expert. Holes for drill sleeves may then be designed into the custom bone graft. Sleeves may then be inserted into the bone graft. The surgeon may then be supplied with directions and the drill size and depth required for each fixation screws.
- the drill may, for instance, incorporate a stop to prevent it penetrating too deeply into the bone of the graft recipient, or into vital structures within the bone such as, but not limited to, arteries, veins or nerves.
- the fixation screws may for instance be made of stainless steel, titanium or resorbable screws, and may be supplied with the graft.
- precursors of the ink may be mixed in relatively small batches.
- the size of the batches mixed into ink may depend on the print speed of the 3-D printer, the print nozzle size of the printer, and the constituents of the precursors, as once mixed, the ink will begin to polymerize with the viscosity of the ink increasing with time. Only as much ink as may be used by the 3-D printer in the time the ink is deliverable by the print nozzle may be mixed at any one time.
- Step 704 “Final Layer Printed?” the 3-D printer may first check to see if it has printed all the layers required to produce the custom bone graft. These layers may have been provided by a programmed module operative on a digital data processing device, and may be the 3-D model of the custom bone graft reduced to consecutive slices that printed in the correct order may result in the required custom bone graft.
- Step 705 “Print Next Layer” the 3-D printer may, if the final layer has not yet been printed, print the next layer. This may be done by, for instance, moving the print nozzle in a raster fashion, depositing ink where required. The printing is preferably performed in a sterilized environment.
- Step 707 Post Print Processing of Graft
- the bone graft may undergo post print processing.
- This post processing step may, for instance, include actions such as, but not limited to, dissolving out the sucrose crystals to provide a porous structure and sterilization of the custom bone graft.
- Step 708 Insertion Custom Bone Graft at Intended Graft Location” the printed and processed custom bone graft may now be inserted into the patient at the intended graft location.
- the ink may include demineralized xenograft bone, synthetic bone substitutes, and other slow reabsorbing biocompatible, bioactive adhesives.
- Alternate formulations of the printing ink may, for instance, include artificial bone substitutes such as, but not limited to, hydroxyapatite, synthetic calcium phosphate ceramic. These may be used instead of, or with natural bone particulates such as, but not limited to, allograft particulate bone, or xenograft particulate bone, or some combination thereof. These may, for instance, be used with synthetically produced bone morphogenetic agents such as, but not limited to, recombinant human Bone Morphogenetic Protein-2 (rhBMP-2).
- rhBMP-2 recombinant human Bone Morphogenetic Protein-2
- Alternate inks may also, or instead, use other biocompatible, bio-active adhesives such as, but not limited to glass polyalkenoate cements, oleic methyl ester based adhesives, or some combination thereof.
- machining of the custom bone grafts may be done using more conventional machining such as computer numerical control (CNC) milling, drilling or routing machines.
- CNC computer numerical control
- the holes for the fixation screws may, for instance, be drilled by CNC machine after the custom graft is produced, or support structure necessary during the printing of a complex shape may be removed by CNC machining, or a starting template may be CNC machined from natural or synthetic bone material to reduce the printing time of the entire custom graft.
- the digital processor 240 may generate a 3-D model in a suitable computer language such as, but not limited to, G-code that may enable a CNC machine to machine a block of bone substitute material.
- the block of bone material may, for instance, be a material such as, but not limited to, REPROBONE® material as supplied by Ceraymisys, Ltd. of Sheffield, England.
- the material used to create the custom bone graft may also, or instead, be a calcium phosphate material such as, but not limited to, hydroxyapatite.
- the machining may, for instance, be accomplished using a multi-axis CNC milling machine such as, but not limited to, a LAVATM CNC 500 milling system manufactured by 3M of Minneapolis, Minn.
- a multi-axis CNC milling machine such as, but not limited to, a LAVATM CNC 500 milling system manufactured by 3M of Minneapolis, Minn.
- a semipermeable, resorbable membrane may be printed on top of the bone graft using a second ink.
- a membrane may, for instance, be made of a co-polymeric blend of poly-vinyl alcohol (PVA) and poly-vinyl pyrrolidone (PVP), as discussed in, for instance, U.S. Pat. No. 7,476,250 issued to Mansmann on Jan. 13, 2009 entitled “Semi-permeable membranes to assist in cartilage repair”, the contents of which are hereby incorporated by reference.
- the semipermeable, resorbable membrane may, for instance, be extend beyond the perimeter of the bone graft in some or all portions of the perimeter, by an amount that may be as much as 1 cm, but is more preferably 0.5 cm.
- a custom bone graft 120 may be produced using a graft negative mold 305 .
- the graft negative mold 305 may, for instance, be generated using a 3-D digital graft model 310 produced from a 3-D image 105 obtained using a X-ray imaging machine 155 such as, but not limited to, a cone-beam X-ray imaging machine 315 .
- FIG. 8 shows a cone-beam X-ray imaging machine 315 to perform a scan of a patient 320 .
- a cone-beam X-ray imaging machine 315 typically contains an X-ray generator 325 and a digital X-ray sensor 330 .
- the X-ray generator 325 and the digital X-ray sensor 330 may, for instance, be housed at opposite extremities of a C-shaped housing 335 .
- the X-ray generator 325 may emit a conical beam of X-rays 340 as the C-shaped housing 335 is rotated 345 around the patient 320 .
- the data captured by the digital X-ray sensor 330 may then be sent to a digital computer 350 that may be running suitable software to convert that data into a 3-D image 360 of a bone defect 355 aka an intended graft location 370 .
- the 3-D image 360 of a bone defect may, for instance, be displayed on a digital display 365 .
- FIG. 9 shows a sectional view of a 3-D image 360 of a bone defect such as, but not limited to, bone and/or cartilage tissue lost to trauma, surgery, infection, normal aging or anatomic abnormalities due to any pathology.
- This method may, for instance, be useful in oral maxillofacial surgery, dental implants, orthopedic surgery or any type of reconstructive hard tissue surgery.
- FIG. 10 shows a sectional view of a computer generated 3-D positive image 375 of a required custom bone graft 120 to be located at a bone site 395 .
- the 3-D positive image 375 of a required custom bone graft may also include additional requirements such as, but not limited to, any required locating screws 380 , or guide paths for screws or tacks to fix the graft in place, space for adhesive 385 and any required structural reinforcement 390 , or guide holes to accommodate reinforcement pins, or some combination thereof.
- FIG. 11 shows a sectional view of a computer generated model of a negative mold 405 of a required graft.
- the negative mold 405 may, for instance, include a top of a negative mold 410 , a left bottom of a negative mold 415 , and a right bottom of a negative mold 420 , or some combination thereof.
- the negative mold 405 of a required graft may, for instance, include suitable relief vent holes 425 , locating cones 430 , or some combination thereof.
- the top of a negative mold 410 may, for instance, be also include suitable locating keys 435 or guide paths for additions such as, but not limited to, locating screws or tacks 380 , structural reinforcement pins 390 or some combination thereof.
- the negative mold 405 of a required graft may be made using a 3-D printer and suitable polymers or photopolymers.
- the negative mold 405 of a required graft may also be made, wholly or in part, using a CNC machine such as, but not limited to, a CNC router, or a combination of 3-D printing and CNC machining.
- FIG. 12 shows a sectional view of a negative mold being used to produce a required graft.
- the negative mold 405 of a required graft may, for instance, be first coated with a suitable release agent 440 and any necessary place holders 450 for any structural reinforcement 390 or locating screws 380 or a combination thereof.
- An FDA approved, porous, biodegradable, biocompatible material 445 that is conducive to osteoinduction and has a load bearing strength comparable to bone, to produce said custom bone graft may then be poured, placed or inserted into the negative mold 405 of a required graft.
- the materials used in producing the customized bone graft from the negative mold may include any of the appropriate materials, and combinations of materials, described above such as, but not limited to, demineralized allograft bone matrix (DMB), or porous Poly Methyl Methacrylate (PMMA) 140 and recombinant human Bone Morphogenetic Protein-2 (rhBMP-2), or some combination thereof.
- DMB demineralized allograft bone matrix
- PMMA porous Poly Methyl Methacrylate
- rhBMP-2 recombinant human Bone Morphogenetic Protein-2
- the material may be a mixture such as, but not limited to, Calcium Sulfate hemihydrate, aka Plaster of Paris, demineralized freeze dried bone (DFDB), or freeze dried bone (FDB), Bone Morphogenetic Proteins (BMP) and an antibiotic such as, but not limited to, Odxucicline.
- DFDB demineralized freeze dried bone
- FDB freeze dried bone
- BMP Bone Morphogenetic Proteins
- an antibiotic such as, but not limited to, Odxucicline.
- Such a medium may, for instance, be a medium such as, but not limited to, polymethylmethacrylate (PMMA), Fibrin Glue, Hydroxyapatite cements or Bio-glass or some combination thereof.
- PMMA polymethylmethacrylate
- Other biomaterials such as, but not limited to, coral, bone-derived materials, bioactive glass ceramics, and synthetic calcium phosphate that may have been mixed with fibrin sealant bone grafting material that may be added by an operator (any particulate material available may function) as well as BMPs, antibiotics or other additives deemed necessary.
- Material that may be in excess of the required amount may be placed so as to accommodate any resorption of the graft.
- the negative lid may be placed by, for instance, guiding cones that may engage negative mold cone holes. Excess material may be squeezed out of the negative lid through suitably place relieve vents and be removed while the bone graft is still in a gelatinous, or liquid state.
- the porous, biodegradable, biocompatible material 445 may be allowed to, or induced to, set, thereby creating a required custom bone graft 120 .
- FIG. 13 shows a sectional view of a graft being placed during surgery.
- the intended graft location 370 may first be coated with a bone adhesive 455 .
- the custom bone graft 120 including any necessary structural reinforcement 390 that may be incorporated into it, may then be placed in the intended graft location 370 .
- the custom bone graft 120 may then be secured in the intended graft location 370 by a suitable means such as, but not limited to, one or more locating screws 380 or tacks, that may be bio-inert and may be bio-absorbable.
- the structural reinforcement 390 and locating screws 380 are preferably biocompatible and may be biodegradable. Suitable biocompatible materials include compositions such as, but not limited to, plastics such as PMMA and stainless steel, polygluconate co-polymer (PGACP) or self-reinforced poly-L-lactic acid polymer (PLLA) or some combination thereof.
- PGACP polygluconate co-polymer
- FIGS. 14 A-D are illustrative of steps that may be used in the process of fabricating a required complex long bone graft 460 .
- FIG. 14 A shows a required complex long bone graft that may be required 460 .
- FIG. 14 B shows a negative mold for a portion 465 of the required complex long bone graft 460 .
- the negative mold is designed to produce one half of the bone graft.
- the negative mold may include a top of a negative mold 410 , a left bottom of a negative mold 415 and a right bottom of a negative mold 420 as well as locating cones 430 and corresponding locating indents 470 , and vent holes 425 .
- FIG. 14 C shows a negative mold being used to produce a portion of the required complex long bone graft.
- the negative mold 405 of a portion of the required graft, containing any required structural reinforcement 390 may have been coated with a suitable release agent and then filled with an appropriate porous, biocompatible material 125 .
- FIG. 14 D shows a complex long bone graft 460 composed of two portions 465 of the bone graft that may contain structural reinforcements 390 and held together by one or more locating screws 380 .
Abstract
A method for producing bone grafts using 3-D printing is employed using a 3-D image of a graft location to produce a 3-D model of the graft. This is printed using a 3-D printer and an ink that produces a porous, biocompatible, biodegradable material that is conducive to osteoinduction. This is porous poly methyl methacrylate (PMMA) made osteoinductive by demineralized bone (DMB). The ink is provided as a precursor powder and liquid. The powder contains DMB, sucrose crystals and a polymerization initiator. The liquid contains methyl methacrylate (MMA). Optional compounds include antibiotics, radio-pacifiers, and compounds to increase biodegradability. Once mixed, the MMA polymerizes to PMMA. The ingredients are proportioned so that the ink is delivered through a 10 gauge print nozzle for about 10 minutes per batch. Once the graft is placed, natural bone gradually replaces the graft.
Description
- This application claims priority to U.S. Provisional Patent Application 61/901,043 filed on Nov. 7, 2013 and to U.S. Provisional Patent Application 61/867,755 filed on Aug. 20, 2013 the entire contents of both of which are hereby fully incorporated by reference.
- The invention relates to producing a custom bone graft, and more particularly to methods of producing custom bone grafts using 3-D printing and/or CNC machining, or a combination thereof.
- Bone grafting is possible because bone tissue, unlike most other tissues, has the ability to regenerate completely if provided the right environment, including a space into which to grow, or a matrix to grow on. As native bone grows, it replaces the graft material, so that over time, the graft is replaced by a fully integrated region of new bone.
- Bone regeneration occurs through osteoinduction, a process in which connective tissue is converted into bone by an appropriate stimulus. Osteoinduction allows bone formation to be induced even at non-skeletal sites and is initiated by bone morphogenetic proteins (BMP).
- The ideal bone graft material would be a strong, porous biocompatible material infused with BMP that did not cause inflammation and would ultimately be reabsorbed into the body as it is replaced by natural bone.
- Bone is composed of 50 to 70% inorganic mineral, 20 to 40% organic collagen matrix, 5 to 10% water, and <3% lipids. The inorganic mineral content of bone is mostly hydroxyapatite [Ca10(PO4)6(OH)2]. The inorganic mineral provides the mechanical strength and rigidity, whereas the organic collagen matrix provides elasticity and flexibility.
- Demineralized bone matrix (DBM) is allograft bone, i.e., bone from other humans, that has had the inorganic, mineral material removed, leaving behind the organic collagen matrix and the BMPs that induce osteoinduction. DBM is conducive to osteoinduction, but lacks the load bearing strength. It is typically used with a 2-4% hyaluronate carrier as a paste or putty to fill a space needing bone, and allows real bone to grow into it within weeks to months.
- The present invention provides a system and method of producing custom bone grafts that are made of a porous, biocompatible material infused with BMPs that can be used as ink in a 3-D printer to produce bone grafts of any desired shape.
- U.S. Patent Application 2011/0151400 published by A. Boiangiu et al. on Jun. 23, 2011 entitled “Dental Bone Implant, Methods for Implanting the Dental Bone Implant and Methods and Systems for Manufacturing Dental Bone Implants” that describes a dental bone implant having a first fitted bone graft sized and shaped to fit tightly to a buccal surface of a periodontal alveolar bone around at least one tooth and to reconstruct at least a portion of one or more periodontal bone defect and a second fitted bone graft sized and shaped to fit tightly to a lingual/palatal surface of a periodontal alveolar bone around at least one tooth and to reconstruct at least an additional portion of at least one periodontal bone defect. The portion and the other portion complementary cover the one or more periodontal bone defects.
- U.S. Patent Application 2004/0120781 published by S. Luca et al. on Jun. 24, 2004 entitled “Customized instruments and parts for medical-dental applications and method and blank for on-site machining of same” that describes a customized prosthesis, or instrument, for medical/dental applications which replicates the desired bone-graft, tooth, or tool, being replaced. The dimensions of the prosthesis, or instrument, are determined by mathematically interpolating key-points that characterize a specific part. A computer controlled machine then cuts the desired part out of a pre-fabricated blank, directly at the site of operation. Methods of the invention relate to selecting the type of part being replaced, identifying and measuring the coordinates of key-points for that part, and initializing the automated machining process. Also, special supporting devices that include pre-fabricated features common between certain parts are used in order to facilitate the machining process. The identification of key-points is done by comparing a schematic drawing of the type of part being replaced to the actual part. A grid is then used to measure the coordinates for those key-points.
- U.S. Pat. No. 6,671,539 issued to Gateno et al. on Dec. 30, 2003 entitled “Method and apparatus for fabricating orthogenetic surgical splints” that describes a method of forming a surgical splint to receive a patient's dentition and thereby align the upper jaw and the lower jaw during surgery includes generating a CT computer model of bone structure, generating a digital dental computer model of the patient's dentition, and then combining the CT computer model and the digital dental computer model to form a composite computer model. The composite computer model may be displayed, and at least one of the upper jaw and lower jaw repositioned relative to the patient's skull and the composite computer model to form a planned position computer model. Using this desired position computer model, a computer model surgical splint of the patient's dentition may be formed, which is then input into a fabrication machine to form a surgical splint. The method also includes forming and displaying the composite computer model. A workstation includes a CT machine, a digital scanner, a computer, an input command mechanism, a display, and a fabricating machine.
- U.S. Pat. No. 8,021,154 issued to Holzner et al. on Sep. 20, 2011 entitled “Method for manufacturing dental prostheses, method for creating a data record and computer-readable medium” that describes a method for manufacturing one or several dental prostheses, comprising the steps of: performing a rapid prototyping method for manufacturing one or several dental prostheses and subsequent working, such as reworking, of the one or several dental prostheses with a machining method, such as a milling method. In addition, a method for creating a data record which can be used for a rapid prototyping method for manufacturing a dental prosthesis wherein an end data record is obtained from a starting data record, so that in at least one area of a dental prosthesis manufactured with the end data record excess material is provided, compared to a dental prosthesis manufactured with the starting data record.
- Various implements are known in the art, but fail to address all of the problems solved by the invention described herein. One embodiment of this invention is illustrated in the accompanying drawings and will be described in more detail herein below.
- The present invention describes systems and methods for producing a custom bone graft. In a preferred embodiment, a 3-D image of an intended graft location may be obtained. This may be achieved by a number of methods, some of which may be discussed in further detail later. Use may, for instance, be made of 3-D image construction techniques such as, but not limited to, obtaining multiple 2-D X-ray images at different orientations, and using computational techniques to convert these into a 3-D image, using a Cone beam imaging device or a cat-scan device, or some combination thereof.
- This 3-D image of the graft location may then be converted into a 3-D digital image of the custom bone graft.
- The custom bone graft may be printed directly using a modified 3-D printer and an ink that transforms into a suitable porous, biocompatible, biodegradable material that is conducive to osteoinduction and has a load bearing strength comparable to bone.
- The custom bone graft may also or instead be made by using a 3-D printer to print a negative form or mold, and the mold may then be used to produce the custom bone graft. In such a process, in a preferred embodiment, the mold may be filled with a mixture of, for instance, Calcium Sulfate hemihydrate, aka Plaster of Paris, demineralized freeze dried bone (DFDB), or freeze dried bone (FDB), Bone Morphogenetic Proteins (BMP) and an antibiotic such as, but not limited to, Doxycycline.
- In a preferred embodiment, the porous, biocompatible material may be porous Poly Methyl Methacrylate (PMMA) and demineralized allograft bone matrix (DMB). The ink for this material may, for instance, be provided as a precursor powder, and a precursor liquid. The precursor powder may, for instance, include demineralized allograft bone matrix (DMB), sucrose crystals and a radical polymerization initiator. The precursor liquid may, for instance, include Methyl Methacrylate (MMA) as well as one or more antibiotics and one or more radio-pacifiers, i.e., compounds that make the graft more radio opaque, or radio dense, so that it may be more visible on X-ray images.
- In a preferred embodiment, the radical polymerization initiator may be benzoyl peroxide, the antibiotic may be gentamicin and the radio-pacifier may be barium sulphate.
- The precursor liquid and powder may be mixed in small batches to produce the ink just before printing. Once the precursors are mixed the MMA may start to polymerize to PMMA. The viscosity of the liquid will increase with time, but suitably proportioned, the ink may be delivered through a 10-14 gauge needle or print nozzle for about 10 to 20 minutes. This may provide a dot size of about 2 mm in diameter, which may be the resolution of the finest detail of the custom bone graft.
- The sucrose crystals provide the porosity to the structure when they are dissolved out in post print processing.
- The structure printed by the ink may also be made biodegradable by the inclusion of cellulose acetate (CA) or cellulose acetate phthalate (CAP), or a combination thereof. The biodegradability may allow the porous PMMA structure to be replaced by natural bone over time.
- Therefore, the present invention succeeds in conferring the following, and others not mentioned, desirable and useful benefits and objectives.
- It is an object of the present invention to provide custom bone grafts suitable for use in disciplines such as, but not limited to, Orthopedics, Plastic Surgery, ENT and Dentistry.
- It is a further object of the present invention to be of use in procedures, including plastic surgery procedures, such as, but not limited to, cleft palate surgical repair, facial and non-facial post trauma or tumor removal reconstruction.
- It is an object of the present invention to provide a method of producing custom bone grafts at a reasonable price.
- It is a further object of the present invention to provide bone grafts that may be an intimate fit to the graft site, as this may increase the chances of bone graft maturation and healing, and because intimate contact is one predictor of a successful surgery.
- It is another object of the present invention to provide a method of producing a custom bone graft using equipment that may be located at a surgeon, or plastic surgeon's, site or office.
- It is an object of the present invention to provide suitable ink for use in suitably modified 3-D printers.
- It is a further object of the present invention to design and fabricate bone grafts to add lost tissue or tissue that was never developed.
-
FIG. 1 shows a preferred embodiment of a method for producing a custom bone graft. -
FIG. 2 shows a magnified section of the mineral structure of bone. -
FIG. 3 shows a magnified section of a demineralized allograft bone matrix (DMB). -
FIG. 4 shows a magnified section of a porous, biocompatible material suitable for use as a bone graft. -
FIG. 5 shows a magnified section of an intermediate stage in producing porous Poly Methyl Methacrylate (PMMA). -
FIG. 6 shows a sematic layout of the ink mixing and print nozzle of a preferred embodiment of the present invention. -
FIG. 7 shows a sematic flow diagram of representative steps of a preferred embodiment of the present invention. -
FIG. 8 shows a cone-beam scan of a patient used by computer software to produce an image of a bone defect. -
FIG. 9 shows a sectional view of a 3-D reconstruction of an imaged defect. -
FIG. 10 shows a sectional view of a computer generated 3-D positive image of a required graft. -
FIG. 11 shows a sectional view of a negative mold of a required graft. -
FIG. 12 shows a sectional view of a negative mold being used to produce a required graft. -
FIG. 13 shows a sectional view of a graft being placed during surgery. -
FIG. 14 A shows a required complex long bone graft. -
FIG. 14 B shows a negative mold for a portion of the required complex long bone graft. -
FIG. 14 C shows a negative mold being used to produce a portion of the required complex long bone graft. -
FIG. 14 D shows a negative mold being used to produce a portion of the required complex long bone graft. - The preferred embodiments of the present invention will now be described with reference to the drawings. Identical elements in the various figures are identified with the same reference numerals.
- Various embodiments of the present invention are described in detail. Such embodiments are provided by way of explanation of the present invention, which is not intended to be limited thereto. In fact, those of ordinary skill in the art may appreciate upon reading the present specification and viewing the present drawings that various modifications and variations can be made thereto.
-
FIG. 1 shows a preferred embodiment of a method for producing a custom bone graft. AnX-ray imaging machine 155 may be used to take one or more images of a region of a patent where acustom bone graft 120 may be needed. These may then be assembled into a 3-D image 105 of the region requiring acustom bone graft 120. A suitably programmeddigital processor 240 may take the 3-D image 105 and transform it into a 3-D model of the region requiring thecustom bone graft 120. This 3-D model may then be used to generate a 3-D model of the requiredcustom bone graft 120. This 3-D model of the requiredcustom bone graft 120 may then be used by a software module operative on thedigital processor 240 to generate instructions for a 3-D printer 115. These instructions may, for instance, take the form of a 3-Ddigital model 110 made up of a series oflayers 245. These layers of a 3-Ddigital model 245 may, for instance, be sized to the resolution of the 3-D printer 115 that may be used to generate thecustom bone graft 120. A 3-D printer 115 may then be used to produce thecustom bone graft 120 layer by layer using an appropriate ink, or series of inks. - In a preferred embodiment, the
X-ray imaging machine 155 may be a Cone Beam 3 D camera such as, but not limited to, the model GX DP-700 supplied by Gendex Dental Systems of Hatfield, Pa. In other embodiments, other imaging devices may be used such as, but not limited to, other computer aided tomography devices, cat-scan devices, 3-D laser cameras or a combination thereof. -
FIG. 2 shows a magnified section of the mineral structure of bone. Mammalian bone may be composed of abone mineral 215 having a lattice or matrix ofvoids 220. Bone may typically be composed of 50 to 70% inorganic mineral, 20 to 40% organic collagen matrix, 5 to 10% water, and <3% lipids. The organic collagen, water, lipids and blood vessels are typically contained within the voids. The inorganic mineral content of bone is mostly hydroxyapatite [Ca10(PO4)6(OH)2]. The inorganic mineral provides the mechanical strength and rigidity, whereas the organic collagen matrix provides elasticity and flexibility. -
FIG. 3 shows a magnified section of a demineralized allograft bone matrix (DMB). The demineralized allograft bone matrix (DMB) 145 may be made up ofcollagen 130, typically formed into a matrix structure, and bone morphogenetic proteins (BMP) 135. Bone morphogenetic proteins (BMPs) are a group of growth factors also known as cytokines and as metabolomes. They were originally discovered through their ability to induce the formation of bone and cartilage, and are now considered to constitute a pivotal group of morphogenetic signals that may orchestrate tissue architecture throughout the body. Although bone morphogenetic proteins (BMP) 135 may be manufactured by genetic engineering, demineralized allograft bone matrix (DMB) 145 is a favored source, and may be used in a paste or putty to facilitate bone regeneration. Demineralized allograft bone matrix (DMB) 145, i.e., allograft bone that has had inorganic minerals removed, may expose more bone morphogenetic proteins (BMP) 135 and therefore facilitate faster growth of natural bone into the paste or putty. Demineralized allograft bone matrix (DMB) 145 does not, however, have the strength of natural bone. Allograft bone is human bone, typically taken from cadavers and bone banks. - Demineralized allograft bone (DMB) 145 may be obtained from, for instance, MAXXEUS Inc., of Kettering, Ohio who sells it under the brand name MAXXEUS™ DBM PUTTY.
-
FIG. 4 shows a magnified section of a porous, biocompatible material suitable for use as a bone graft. The porous,biocompatible material 125 may, for instance, be made up of a biocompatible, porousstructural support 250 made conducive to osteoinduction by the presence of bone morphogenetic proteins (BMP) 135. - In a preferred embodiment, the biocompatible, porous
structural support 250 may, for instance, be porous Poly Methyl Methacrylate (PMMA) 140 and the bone morphogenetic proteins (BMP) 135 may, for instance, be demineralized allograft bone matrix (DBM) 145. The bone morphogenetic proteins (BMP) 135 may also, or instead, be a synthetically produced compound such as, but not limited to, recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) as provided by, for instance, Medtronic Inc. of Minneapolis, Minn. in their INFUSE Bone Graft material. - Poly Methyl Methacrylate (PMMA) 140 is a synthetic polymer of methyl methacrylate, whose biocompatibility was, apparently, discovered by accident during WWII when RAF pilots suffered eye injuries from the destruction of their side widows. Hawker Hurricane pilots, whose windows were made of glass, suffered severe rejection/infection in the vicinity of the glass splinters in their eyes, while Spitfire pilots, whose side windows were made of PMMA suffered no rejection/infection in the vicinity of the PMMA splinters. This good degree of compatibility with human tissue has been exploited by using PMMA for intraocular eye lenses that replace cataract damaged lenses, and in orthopedic surgery. In orthopedic surgery it is used as a grout, or bone cement, to stabilize join implants. PMMA bone cement such as, but not limited to, SIMPLEX P™ BONE CEMENT sold by the Stryker Corporation of Kalamazoo, Mich. is typically supplied as a powder and a liquid. The ingredients of Stryker's SIMPLEX P™ BONECEMENT are reported to be 75% methyl methacrylate; 15% polymethylmethacrylate (PMMA); 10% Barium Sulfate for radio-opaqueness, and an undisclosed quantity of benzoyl peroxide to initiate the radical induced polymerization of the MMA to PMMA. The amount of the radical polymerization initiator, benzoyl peroxide, may be crucial for determining the mixing, handling, and setting characteristics of the bone cement.
- In orthopedic use, the powder and liquid precursors are mixed about 10 minutes before being used. Mixing the powder and liquid initiates the polymerization, which may take up to several hours to complete. They are either applied as putty, or delivered to the required site by means of needles that range in size from 10 to 14 gauges, i.e., in the vicinity of 2 mm internal bore needles.
-
FIG. 5 shows a magnified section of an intermediate stage in producing porous poly methyl methacrylate (PMMA). - The porous Poly Methyl Methacrylate (PMMA) 140 may be produced by including
sucrose crystals 170 of the appropriate size in the MMA being polymerized. After the MMA is fully polymerized from its liquid form to solid form, thesucrose crystals 170 may be dissolved out, leaving behind a porous PMMA structure. - This method of producing a porous PMMA structure was developed in order to overcome some shortcomings of existing PMMA bone cement, as reported by A. Rijke et al in an article entitled “Porous Acrylic Cement” published in J Biomed Mater Res. 1977 May; 11(3):373-94, the contents of which are hereby incorporated by reference.
- Shortcomings of PMMA bone cement include that it heats up to 82.5° C. (160.5° F.) while setting. This is high enough to cause thermal necrosis of neighboring tissue, or any biomaterial such as, but not limited to, collagen and bone morphogenetic proteins (BMP) that may be found in demineralized allograft bone matrix (DMB).
- By modifying the cement composition through the addition of soluble, nontoxic filler such as sucrose or tri-calcium phosphate which does not impair the workability of the material during surgery, a significant improvement in the performance of the cement can be achieved. Because the filler replaces part of the acrylic components, less heat is generated during curing while the filler itself acts as a heat sink.
- Porous cement may be obtained provided that a critical minimum percentage loading of the filler is exceeded so that the filler crystals will make physical contact with each other. The value of this percentage depends on both crystal modification and size. With crystals in the 125-175 micron range, the critical minimum percentage may be in the range of 20-28 wt. % loading. Above 30%, the interconnecting pore size increases and may allow good tissue ingrowth into the pores. The introduction of filler and pores may cause a drop in strength, but the tensile strength of modified cement containing up to 40% pores and sucrose lies between 0.7 and 1.5 kg/mm2′, which is in the same range as that of bone.
- Poly methyl methacrylate (PMMA) may be made biodegradable by the addition of cellulose acetate (CA) 255 or cellulose acetate phthalate (CAP) 260, as described in, for instance, an article by D. Batt et al. entitled “Biodegradability of PMMA Blends with Some Cellulose Derivatives”, published in Journal of Polymers and the Environment, October 2006, Volume 14, Issue 4, pp. 385-392, the contents of which are hereby incorporated by reference.
- The rate of biodegradation may be controlled by the relative amount of the compound use to increase the biodegradability of the ink, or the product produced by the polymerized ink.
-
FIG. 6 shows a sematic layout of an ink mixing and print nozzle of a preferred embodiment of the present invention. - In a preferred embodiment, the ink may contain structural material ingredients; ingredients to form a porous, resorbable, matrix; and additives such as, but not limited to, synthetic BMPs, antibiotic chemicals, anti-inflammatory chemicals and radiopaque chemicals, or some combination thereof.
- The structural material ingredients may, for instance, include a substance such as, but not limited to, Hydroxyapatite, allograft particulate bone, xenograft particulate bone or some combination thereof.
- The ingredients to form a porous, resorbable matrix may include substances such as, but not limited to, methyl methacrylate, cellulose, resorbable cements, or precursors to resorbable cements or some combination thereof.
- Antibiotic additives may include any suitable antibiotic, or antibiotic combinations, such as, but not limited to, demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline, thiamphenicol, ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, nalidixic acid, norfloxacin, ofloxacin, bacitracin, colistin, amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin/tazobactam, ticarcillin/clavulanate, or some combination thereof.
- In a preferred embodiment, the ink may, for instance, be supplied in the form of a
precursor powder 190 and aprecursor liquid 195. These may be feed to separate containers in the 3-D printer. Prior to printing, a quantity of theprecursor powder 190 and theprecursor liquid 195 may be mixed to form theink 150 to be used for printing thecustom bone graft 120. The printing may be accomplished by delivering quantities of theink 150 via a suitablysized print nozzle 235 that may be moved in araster scan 230 with respect to thecustom bone graft 120 being printed. - The
precursor powder 190 of theink 150 may, for instance, contain a variety of ingredients such as, but not limited to, demineralized allograft bone matrix (DMB) 145,sucrose crystals 170, radical polymerization initiator 175 or some combination thereof. - The radical polymerization initiator 175 may, for instance, be a compound such as, but not limited to, di-benzoyl peroxide (BPO).
- The
precursor liquid 195 may for, instance, contain a variety of ingredients such as, but not limited to, methyl methacrylate (MMA) 165, a radio-pacifier 185, an antibiotic 180, and a compound to increase the biodegradability 265, or some combination thereof. - The radio-pacifier 185 may, for instance, be a compound such as, but not limited to, zirconium dioxide (ZrO2) or barium sulphate (BaSO4) or some combination thereof.
- The antibiotic 180 may, for instance, be a compound such as, but not limited to, amoxicillin, doxycycline, gentamicin or clindamycin or some combination thereof.
- The compound to increase the biodegradability 265 may, for instance, be a compound such as, but not limited to, cellulose acetate (CA), or cellulose acetate phthalate (CAP) or some combination thereof.
-
FIG. 7 shows a sematic flow diagram of representative steps of a preferred embodiment of the present invention. - In
Step 701 “Obtain 3-D Image of Graft Location”, the patient may be imaged using one of a number of well-known techniques for obtaining a 3-D image such as, but not limited to, a cone beam 3-D camera, computer aided tomography, 3-D laser cameras or a combination thereof. - In Step 702 “Create 3-D Model of Custom Bone Graft”, the images obtained in
step 701 may be used by a suitably constructed computer program operable on a suitable digital data processor, to generate a 3-D model of a custom bone graft for the patient. In this step, the computer program may also use a database of standard models of human body parts to provide guidance on areas that may not be adequately described or detailed by the 3-D images. The custom bone graft may also include provision for locating fixation screws that might be added using guidance from a qualified professional. - Fixation screws, including their size, location and orientation may be designed on the computer model by a competent expert. Holes for drill sleeves may then be designed into the custom bone graft. Sleeves may then be inserted into the bone graft. The surgeon may then be supplied with directions and the drill size and depth required for each fixation screws. The drill may, for instance, incorporate a stop to prevent it penetrating too deeply into the bone of the graft recipient, or into vital structures within the bone such as, but not limited to, arteries, veins or nerves. Once the holes are drilled, the sleeves may be removed and the fixation screws inserted by the surgeon to hold the graft in place. The fixation screws may for instance be made of stainless steel, titanium or resorbable screws, and may be supplied with the graft.
- In
Step 703 “Mix Precursor Powder & Liquid to Form Ink”, precursors of the ink may be mixed in relatively small batches. The size of the batches mixed into ink may depend on the print speed of the 3-D printer, the print nozzle size of the printer, and the constituents of the precursors, as once mixed, the ink will begin to polymerize with the viscosity of the ink increasing with time. Only as much ink as may be used by the 3-D printer in the time the ink is deliverable by the print nozzle may be mixed at any one time. - In
Step 704 “Final Layer Printed?” the 3-D printer may first check to see if it has printed all the layers required to produce the custom bone graft. These layers may have been provided by a programmed module operative on a digital data processing device, and may be the 3-D model of the custom bone graft reduced to consecutive slices that printed in the correct order may result in the required custom bone graft. - In
Step 705 “Print Next Layer”, the 3-D printer may, if the final layer has not yet been printed, print the next layer. This may be done by, for instance, moving the print nozzle in a raster fashion, depositing ink where required. The printing is preferably performed in a sterilized environment. - In
Step 707 “Post Print Processing of Graft”, once the 3-D printer has printed all the required layers that constitute the custom bone graft, the bone graft may undergo post print processing. This post processing step may, for instance, include actions such as, but not limited to, dissolving out the sucrose crystals to provide a porous structure and sterilization of the custom bone graft. - In Step 708 “Insert Custom Bone Graft at Intended Graft Location” the printed and processed custom bone graft may now be inserted into the patient at the intended graft location.
- In alternate embodiments, the ink may include demineralized xenograft bone, synthetic bone substitutes, and other slow reabsorbing biocompatible, bioactive adhesives.
- Alternate formulations of the printing ink may, for instance, include artificial bone substitutes such as, but not limited to, hydroxyapatite, synthetic calcium phosphate ceramic. These may be used instead of, or with natural bone particulates such as, but not limited to, allograft particulate bone, or xenograft particulate bone, or some combination thereof. These may, for instance, be used with synthetically produced bone morphogenetic agents such as, but not limited to, recombinant human Bone Morphogenetic Protein-2 (rhBMP-2).
- Alternate inks may also, or instead, use other biocompatible, bio-active adhesives such as, but not limited to glass polyalkenoate cements, oleic methyl ester based adhesives, or some combination thereof.
- Although producing the custom bone grafts has been discussed with respect to 3-D printing, some or all of the machining of the custom bone grafts may be done using more conventional machining such as computer numerical control (CNC) milling, drilling or routing machines. The holes for the fixation screws may, for instance, be drilled by CNC machine after the custom graft is produced, or support structure necessary during the printing of a complex shape may be removed by CNC machining, or a starting template may be CNC machined from natural or synthetic bone material to reduce the printing time of the entire custom graft.
- In order to do such machining the
digital processor 240 may generate a 3-D model in a suitable computer language such as, but not limited to, G-code that may enable a CNC machine to machine a block of bone substitute material. The block of bone material may, for instance, be a material such as, but not limited to, REPROBONE® material as supplied by Ceraymisys, Ltd. of Sheffield, England. The material used to create the custom bone graft may also, or instead, be a calcium phosphate material such as, but not limited to, hydroxyapatite. - In a preferred embodiment, the machining may, for instance, be accomplished using a multi-axis CNC milling machine such as, but not limited to, a LAVA™ CNC 500 milling system manufactured by 3M of Minneapolis, Minn.
- In a further preferred embodiment of the invention, a semipermeable, resorbable membrane may be printed on top of the bone graft using a second ink. Such a membrane may, for instance, be made of a co-polymeric blend of poly-vinyl alcohol (PVA) and poly-vinyl pyrrolidone (PVP), as discussed in, for instance, U.S. Pat. No. 7,476,250 issued to Mansmann on Jan. 13, 2009 entitled “Semi-permeable membranes to assist in cartilage repair”, the contents of which are hereby incorporated by reference. The semipermeable, resorbable membrane may, for instance, be extend beyond the perimeter of the bone graft in some or all portions of the perimeter, by an amount that may be as much as 1 cm, but is more preferably 0.5 cm.
- In yet a further preferred embodiment of the invention, a
custom bone graft 120 may be produced using a graft negative mold 305. The graft negative mold 305 may, for instance, be generated using a 3-D digital graft model 310 produced from a 3-D image 105 obtained using aX-ray imaging machine 155 such as, but not limited to, a cone-beam X-ray imaging machine 315. -
FIG. 8 shows a cone-beam X-ray imaging machine 315 to perform a scan of apatient 320. A cone-beam X-ray imaging machine 315 typically contains anX-ray generator 325 and adigital X-ray sensor 330. TheX-ray generator 325 and thedigital X-ray sensor 330 may, for instance, be housed at opposite extremities of a C-shapedhousing 335. TheX-ray generator 325 may emit a conical beam ofX-rays 340 as the C-shapedhousing 335 is rotated 345 around thepatient 320. The data captured by thedigital X-ray sensor 330 may then be sent to adigital computer 350 that may be running suitable software to convert that data into a 3-D image 360 of abone defect 355 aka an intendedgraft location 370. The 3-D image 360 of a bone defect may, for instance, be displayed on adigital display 365. -
FIG. 9 shows a sectional view of a 3-D image 360 of a bone defect such as, but not limited to, bone and/or cartilage tissue lost to trauma, surgery, infection, normal aging or anatomic abnormalities due to any pathology. This method may, for instance, be useful in oral maxillofacial surgery, dental implants, orthopedic surgery or any type of reconstructive hard tissue surgery. -
FIG. 10 shows a sectional view of a computer generated 3-Dpositive image 375 of a requiredcustom bone graft 120 to be located at abone site 395. - In a preferred embodiment, the 3-D
positive image 375 of a required custom bone graft may also include additional requirements such as, but not limited to, any required locatingscrews 380, or guide paths for screws or tacks to fix the graft in place, space for adhesive 385 and any requiredstructural reinforcement 390, or guide holes to accommodate reinforcement pins, or some combination thereof. -
FIG. 11 shows a sectional view of a computer generated model of anegative mold 405 of a required graft. Thenegative mold 405 may, for instance, include a top of anegative mold 410, a left bottom of anegative mold 415, and a right bottom of anegative mold 420, or some combination thereof. Thenegative mold 405 of a required graft may, for instance, include suitable relief vent holes 425, locatingcones 430, or some combination thereof. The top of anegative mold 410 may, for instance, be also include suitable locating keys 435 or guide paths for additions such as, but not limited to, locating screws or tacks 380, structural reinforcement pins 390 or some combination thereof. - In a preferred embodiment, the
negative mold 405 of a required graft may be made using a 3-D printer and suitable polymers or photopolymers. Thenegative mold 405 of a required graft may also be made, wholly or in part, using a CNC machine such as, but not limited to, a CNC router, or a combination of 3-D printing and CNC machining. -
FIG. 12 shows a sectional view of a negative mold being used to produce a required graft. Thenegative mold 405 of a required graft may, for instance, be first coated with asuitable release agent 440 and anynecessary place holders 450 for anystructural reinforcement 390 or locatingscrews 380 or a combination thereof. An FDA approved, porous, biodegradable,biocompatible material 445 that is conducive to osteoinduction and has a load bearing strength comparable to bone, to produce said custom bone graft may then be poured, placed or inserted into thenegative mold 405 of a required graft. - The materials used in producing the customized bone graft from the negative mold may include any of the appropriate materials, and combinations of materials, described above such as, but not limited to, demineralized allograft bone matrix (DMB), or porous Poly Methyl Methacrylate (PMMA) 140 and recombinant human Bone Morphogenetic Protein-2 (rhBMP-2), or some combination thereof.
- In a preferred embodiment of the present invention, the material may be a mixture such as, but not limited to, Calcium Sulfate hemihydrate, aka Plaster of Paris, demineralized freeze dried bone (DFDB), or freeze dried bone (FDB), Bone Morphogenetic Proteins (BMP) and an antibiotic such as, but not limited to, Odxucicline.
- Further materials including, but not limited to, solidifying resorbable or non resorbable possibly osteoconductive, osteoinductive medium that may be placed inside the negative mold. Such a medium may, for instance, be a medium such as, but not limited to, polymethylmethacrylate (PMMA), Fibrin Glue, Hydroxyapatite cements or Bio-glass or some combination thereof. Other biomaterials such as, but not limited to, coral, bone-derived materials, bioactive glass ceramics, and synthetic calcium phosphate that may have been mixed with fibrin sealant bone grafting material that may be added by an operator (any particulate material available may function) as well as BMPs, antibiotics or other additives deemed necessary. Material that may be in excess of the required amount may be placed so as to accommodate any resorption of the graft. The negative lid may be placed by, for instance, guiding cones that may engage negative mold cone holes. Excess material may be squeezed out of the negative lid through suitably place relieve vents and be removed while the bone graft is still in a gelatinous, or liquid state.
- The porous, biodegradable,
biocompatible material 445 may be allowed to, or induced to, set, thereby creating a requiredcustom bone graft 120. -
FIG. 13 shows a sectional view of a graft being placed during surgery. The intendedgraft location 370 may first be coated with abone adhesive 455. Thecustom bone graft 120, including any necessarystructural reinforcement 390 that may be incorporated into it, may then be placed in the intendedgraft location 370. Thecustom bone graft 120 may then be secured in the intendedgraft location 370 by a suitable means such as, but not limited to, one or more locating screws 380 or tacks, that may be bio-inert and may be bio-absorbable. Thestructural reinforcement 390 and locatingscrews 380 are preferably biocompatible and may be biodegradable. Suitable biocompatible materials include compositions such as, but not limited to, plastics such as PMMA and stainless steel, polygluconate co-polymer (PGACP) or self-reinforced poly-L-lactic acid polymer (PLLA) or some combination thereof. -
FIGS. 14 A-D are illustrative of steps that may be used in the process of fabricating a required complexlong bone graft 460. -
FIG. 14 A shows a required complex long bone graft that may be required 460. -
FIG. 14 B shows a negative mold for aportion 465 of the required complexlong bone graft 460. In the instance shown inFIG. 14 B, the negative mold is designed to produce one half of the bone graft. The negative mold may include a top of anegative mold 410, a left bottom of anegative mold 415 and a right bottom of anegative mold 420 as well as locatingcones 430 and corresponding locating indents 470, and ventholes 425. -
FIG. 14 C shows a negative mold being used to produce a portion of the required complex long bone graft. Thenegative mold 405 of a portion of the required graft, containing any requiredstructural reinforcement 390, may have been coated with a suitable release agent and then filled with an appropriate porous,biocompatible material 125. -
FIG. 14 D shows a complexlong bone graft 460 composed of twoportions 465 of the bone graft that may containstructural reinforcements 390 and held together by one or more locating screws 380. - Although this invention has been described with a certain degree of particularity, it is to be understood that the present disclosure has been made only by way of illustration and that numerous changes in the details of construction and arrangement of parts may be resorted to without departing from the spirit and the scope of the invention. cm What is claimed:
Claims (23)
1. A method for producing a custom bone graft, comprising:
obtaining a 3-D image of an intended graft location;
creating a 3-D digital model of said custom bone graft using said 3-D image; and
creating, using a 3-D printer said custom bone graft using an ink that dries or reacts to form a porous, biodegradable, biocompatible material that is conducive to osteoinduction and has a load bearing strength comparable to bone.
2. The method of claim 1 wherein said porous, biodegradable, biocompatible material comprises collagen and bone morphogenetic proteins (BMP).
3. The method of claim 1 wherein said porous, biodegradable, biocompatible material comprises porous Poly Methyl Methacrylate (PMMA) and demineralized allograft bone matrix (DMB).
4. The method of claim 3 wherein said ink comprises Methyl Methacrylate (MMA), demineralized allograft bone matrix (DMB), sucrose crystals and a radical polymerization initiator.
5. The method of claim 4 wherein said radical polymerization initiator comprises benzoyl peroxide.
6. The method of claim 4 wherein said ink further comprises an antibiotic.
7. The method of claim 6 wherein said antibiotic consists of one of amoxicillin, doxycycline, gentamicin and clindamycin, or some combination thereof.
8. The method of claim 4 wherein said ink further comprises a radio-pacifier.
9. The method of claim 8 wherein said radio-pacifier consists of one of zirconium dioxide (ZrO2) and barium sulphate (BaSO4) or some combination thereof.
10. The method of claim 4 wherein said ink further comprises a compound to increase the biodegradability of said ink.
11. The method of claim 10 wherein said compound to increase the biodegradability of said ink consists of one of cellulose acetate (CA) and cellulose acetate phthalate (CAP) or a combination thereof.
12. The method of claim 3 wherein said ink is comprised of a precursor powder and a precursor liquid, and wherein said powder is comprised of demineralized allograft bone matrix (DMB), sucrose crystals and a radical polymerization initiator, and said liquid comprises methyl methacrylate (MMA), and when said precursor powder and said precursor liquid are mixed prior to form said ink in said 3-D printer.
13. The method of claim 1 wherein said 3-D image is obtained using one or more X-ray images.
14. The method of claim 1 wherein said 3-D digital model further comprises using a standard model of a body part.
15. The method of claim 1 further including a semipermeable, resorbable membrane printed on top of said custom bone graft using a second ink.
16. The method of claim 15 wherein said second ink comprises poly-vinyl alcohol (PVA) and poly-vinyl pyrrolidone (PVP).
17. The method of claim 1 wherein said 3-D image is obtained using a Cone beam imaging device or a cat-scan device.
18. The method of claim 1 wherein said porous, biodegradable, biocompatible material comprises a resorbable cement, cellulose, a synthetic bone morphogenetic protein, and one of hydroxyapatite, allograft particulate bone, xenograft particulate bone, or a combination thereof.
19. The method of claim 18 wherein said resorbable cement comprises porous Poly Methyl Methacrylate (PMMA), and said synthetic bone morphogenetic protein comprises recombinant human Bone Morphogenetic Protein-2 (rhBMP-2).
20. A method for producing a custom bone graft, comprising:
obtaining a 3-D image of an intended graft location;
creating a 3-D digital model of said custom bone graft using said 3-D image;
generating a 3-D digital graft model 310 of a graft negative mold 305 for said custom bone graft using said 3-D digital model; and
creating, using said 3-D digital mold and a porous, biodegradable, biocompatible material that is conducive to osteoinduction and has a load bearing strength comparable to bone, to produce said custom bone graft.
21. The method of claim 20 wherein generating a 3-D digital mold of a negative mold for said custom bone graft further comprises using a 3-D printer.
22. The method of claim 20 wherein said porous, biodegradable, biocompatible material comprises collagen and bone morphogenetic proteins (BMP).
23. The method of claim 20 wherein said porous, biodegradable, biocompatible material comprises porous Poly Methyl Methacrylate (PMMA) and demineralized allograft bone matrix (DMB).
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/447,085 US20150054195A1 (en) | 2013-08-20 | 2014-07-30 | Method for 3-D Printing a Custom Bone Graft |
US15/285,169 US20170024501A1 (en) | 2013-08-20 | 2016-10-04 | Method for 3-d printing a custom bone graft |
US16/395,273 US10579755B2 (en) | 2013-08-20 | 2019-04-26 | Method for 3-D printing a custom bone graft |
US16/747,002 US11556682B2 (en) | 2013-08-20 | 2020-01-20 | Method for 3-D printing a custom bone graft |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361867755P | 2013-08-20 | 2013-08-20 | |
US201361901043P | 2013-11-07 | 2013-11-07 | |
US14/447,085 US20150054195A1 (en) | 2013-08-20 | 2014-07-30 | Method for 3-D Printing a Custom Bone Graft |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/285,169 Continuation-In-Part US20170024501A1 (en) | 2013-08-20 | 2016-10-04 | Method for 3-d printing a custom bone graft |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150054195A1 true US20150054195A1 (en) | 2015-02-26 |
Family
ID=52479651
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/447,085 Abandoned US20150054195A1 (en) | 2013-08-20 | 2014-07-30 | Method for 3-D Printing a Custom Bone Graft |
US15/285,169 Abandoned US20170024501A1 (en) | 2013-08-20 | 2016-10-04 | Method for 3-d printing a custom bone graft |
US16/395,273 Active US10579755B2 (en) | 2013-08-20 | 2019-04-26 | Method for 3-D printing a custom bone graft |
US16/747,002 Active 2035-11-05 US11556682B2 (en) | 2013-08-20 | 2020-01-20 | Method for 3-D printing a custom bone graft |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/285,169 Abandoned US20170024501A1 (en) | 2013-08-20 | 2016-10-04 | Method for 3-d printing a custom bone graft |
US16/395,273 Active US10579755B2 (en) | 2013-08-20 | 2019-04-26 | Method for 3-D printing a custom bone graft |
US16/747,002 Active 2035-11-05 US11556682B2 (en) | 2013-08-20 | 2020-01-20 | Method for 3-D printing a custom bone graft |
Country Status (1)
Country | Link |
---|---|
US (4) | US20150054195A1 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150374450A1 (en) * | 2014-06-30 | 2015-12-31 | Bacterin International, Inc. | Manufacture of biomaterial implants via three-dimensional printing technology |
WO2017010811A1 (en) * | 2015-07-13 | 2017-01-19 | 한양대학교 산학협력단 | Personalized alveolar bone tissue and method for manufacturing same |
US20170273795A1 (en) * | 2016-03-25 | 2017-09-28 | Tornier Sas | Bone graft shaper & patient specific bone graft |
WO2017173333A3 (en) * | 2016-03-31 | 2017-11-09 | Lee Ernesto A | Method, devices and articles for conducting subperiosteal minimally invasive aesthetic jaw bone grafting augmentation |
WO2018059912A1 (en) * | 2016-09-28 | 2018-04-05 | Evonik Röhm Gmbh | Production and use of porous bead polymers in 3d printing using the binder jetting method |
US10064726B1 (en) | 2017-04-18 | 2018-09-04 | Warsaw Orthopedic, Inc. | 3D printing of mesh implants for bone delivery |
CN108765554A (en) * | 2018-05-21 | 2018-11-06 | 四川大学 | Heterogeneous core three-dimensional rebuilding method based on super dimension |
US10238507B2 (en) | 2015-01-12 | 2019-03-26 | Surgentec, Llc | Bone graft delivery system and method for using same |
US10442182B2 (en) | 2015-11-24 | 2019-10-15 | The Texas A&M University System | In vivo live 3D printing of regenerative bone healing scaffolds for rapid fracture healing |
US10589465B2 (en) * | 2014-08-13 | 2020-03-17 | Lg Electronics Inc. | Terminal apparatus, system comprising terminal apparatus, and method for controlling terminal apparatus |
US10687828B2 (en) | 2018-04-13 | 2020-06-23 | Surgentec, Llc | Bone graft delivery system and method for using same |
US10695978B2 (en) | 2016-04-12 | 2020-06-30 | Evonik Operations Gmbh | Spray-dried soft-phase emulsion polymer for filling the gussets in bead polymer layers in a binder jetting method |
US10716676B2 (en) | 2008-06-20 | 2020-07-21 | Tornier Sas | Method for modeling a glenoid surface of a scapula, apparatus for implanting a glenoid component of a shoulder prosthesis, and method for producing such a component |
US10793731B2 (en) | 2016-04-20 | 2020-10-06 | Evonik Operations Gmbh | Bead polymer made of hard phase with domains of a soft phase |
US10814369B2 (en) | 2015-08-07 | 2020-10-27 | Arconic Technologies Llc | Architectural manufactures, apparatus and methods using additive manufacturing techniques |
CN112188952A (en) * | 2018-03-21 | 2021-01-05 | 埃森提姆公司 | High-speed extrusion 3-D printing system |
WO2021016288A1 (en) | 2019-07-25 | 2021-01-28 | D2 Medical Llc | Bone-derived thermoplastic filament and method of manufacture |
US10959742B2 (en) | 2017-07-11 | 2021-03-30 | Tornier, Inc. | Patient specific humeral cutting guides |
US10961813B2 (en) | 2017-12-05 | 2021-03-30 | Saudi Arabian Oil Company | Wellbore casing liner printing |
US20210106723A1 (en) * | 2019-10-11 | 2021-04-15 | Advanced Solutions Life Sciences, Llc | Bone graft and methods of fabrication and use |
KR20210065694A (en) * | 2019-11-27 | 2021-06-04 | 울산과학기술원 | A method for manufacturing artificial cornea |
US11039871B2 (en) | 2017-06-23 | 2021-06-22 | Ernesto A. Lee | Subperiosteal syringe device for admitting bone graft material into a subperiosteal locus |
US11065016B2 (en) | 2015-12-16 | 2021-07-20 | Howmedica Osteonics Corp. | Patient specific instruments and methods for joint prosthesis |
US11116647B2 (en) | 2018-04-13 | 2021-09-14 | Surgentec, Llc | Bone graft delivery system and method for using same |
WO2021214515A1 (en) * | 2020-04-20 | 2021-10-28 | Mandelli Federico | Insert and procedure for bone regeneration |
US11166733B2 (en) | 2017-07-11 | 2021-11-09 | Howmedica Osteonics Corp. | Guides and instruments for improving accuracy of glenoid implant placement |
USD950059S1 (en) | 2017-03-31 | 2022-04-26 | Ernesto A. Lee | Subperiosteal surgical instrument |
US11364323B2 (en) | 2018-09-17 | 2022-06-21 | Rejuvablast LLC | Combination grafts for tissue repair or regeneration applications |
IT202100019154A1 (en) * | 2021-07-20 | 2023-01-20 | Tsq Global S R L | DEVICE FOR OSTEOSYNTHESIS |
US11660196B2 (en) | 2017-04-21 | 2023-05-30 | Warsaw Orthopedic, Inc. | 3-D printing of bone grafts |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201700020563A1 (en) * | 2017-02-23 | 2018-08-23 | Intelligenza Trasparente S R L | System and Method for the realization of a cranial operculum of a living being |
US20180296343A1 (en) * | 2017-04-18 | 2018-10-18 | Warsaw Orthopedic, Inc. | 3-d printing of porous implants |
CN110730800B (en) | 2017-05-26 | 2022-08-19 | 无限材料解决方案有限公司 | Aqueous polymer composition |
CN109376397B (en) * | 2018-09-05 | 2023-11-03 | 成都数模码科技有限公司 | Intelligent design method and system for three-dimensional mold |
US10799295B1 (en) * | 2019-04-23 | 2020-10-13 | Kristian Tjon | Computer-aided design and preparation of bone graft |
CN111231303A (en) * | 2020-02-26 | 2020-06-05 | 中国人民解放军联勤保障部队第九〇〇医院 | High-simulation tumor model manufacturing method based on 3D printing technology |
US20230074737A1 (en) * | 2021-09-09 | 2023-03-09 | Dip, Llc | Customized three-dimensional scaffold for oral and maxillofacial bone grafting |
WO2024033692A1 (en) * | 2022-08-12 | 2024-02-15 | Eskandamejad Vida | A method for customized synthetic block graft with 3-dimensional stereolithography |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204055A (en) * | 1989-12-08 | 1993-04-20 | Massachusetts Institute Of Technology | Three-dimensional printing techniques |
US6786930B2 (en) * | 2000-12-04 | 2004-09-07 | Spineco, Inc. | Molded surgical implant and method |
US20050021142A1 (en) * | 2003-02-26 | 2005-01-27 | Therics, Inc. | Method of manufacture, installation, and system for a sinus lift bone graft |
US20050113930A1 (en) * | 2003-02-26 | 2005-05-26 | Therics, Inc. | Method of manufacture, installation, and system for an alveolar ridge augmentation graft |
US20060058632A1 (en) * | 2004-09-13 | 2006-03-16 | Mcburnett Doyle H | Method of medical modeling |
US7476250B1 (en) * | 1999-04-06 | 2009-01-13 | Mansmann Kevin A | Semi-permeable membranes to assist in cartilage repair |
US20100013650A1 (en) * | 2008-07-18 | 2010-01-21 | Hon Hai Precision Industry Co., Ltd. | Shake responsive media player |
US20100324692A1 (en) * | 2007-04-17 | 2010-12-23 | Biomet Manufacturing Corp. | Method and Apparatus for Manufacturing an Implant |
US8473305B2 (en) * | 2007-04-17 | 2013-06-25 | Biomet Manufacturing Corp. | Method and apparatus for manufacturing an implant |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003070816A (en) * | 2001-08-30 | 2003-03-11 | Pentax Corp | Designing method for implant, and implant |
US20050098915A1 (en) * | 2003-11-07 | 2005-05-12 | Smith & Nephew Inc. | Manufacture of bone graft substitutes |
EP1961433A1 (en) * | 2007-02-20 | 2008-08-27 | National University of Ireland Galway | Porous substrates for implantation |
JP2012530548A (en) * | 2009-06-17 | 2012-12-06 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | Tooth scaffolding |
MX2015002710A (en) * | 2012-09-04 | 2015-07-23 | Anthrogenesis Corp | Methods of tissue generation. |
US10730232B2 (en) * | 2013-11-19 | 2020-08-04 | Guill Tool & Engineering Co, Inc. | Coextruded, multilayer and multicomponent 3D printing inputs |
WO2016019078A1 (en) * | 2014-07-30 | 2016-02-04 | Tufts University | Three dimensional printing of bio-ink compositions |
US10409235B2 (en) * | 2014-11-12 | 2019-09-10 | Siemens Healthcare Gmbh | Semantic medical image to 3D print of anatomic structure |
US10751943B2 (en) * | 2015-08-24 | 2020-08-25 | Siemens Healthcare Gmbh | Personalized creation from medical imaging |
US10064726B1 (en) * | 2017-04-18 | 2018-09-04 | Warsaw Orthopedic, Inc. | 3D printing of mesh implants for bone delivery |
-
2014
- 2014-07-30 US US14/447,085 patent/US20150054195A1/en not_active Abandoned
-
2016
- 2016-10-04 US US15/285,169 patent/US20170024501A1/en not_active Abandoned
-
2019
- 2019-04-26 US US16/395,273 patent/US10579755B2/en active Active
-
2020
- 2020-01-20 US US16/747,002 patent/US11556682B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204055A (en) * | 1989-12-08 | 1993-04-20 | Massachusetts Institute Of Technology | Three-dimensional printing techniques |
US7476250B1 (en) * | 1999-04-06 | 2009-01-13 | Mansmann Kevin A | Semi-permeable membranes to assist in cartilage repair |
US6786930B2 (en) * | 2000-12-04 | 2004-09-07 | Spineco, Inc. | Molded surgical implant and method |
US20050021142A1 (en) * | 2003-02-26 | 2005-01-27 | Therics, Inc. | Method of manufacture, installation, and system for a sinus lift bone graft |
US20050113930A1 (en) * | 2003-02-26 | 2005-05-26 | Therics, Inc. | Method of manufacture, installation, and system for an alveolar ridge augmentation graft |
US20060058632A1 (en) * | 2004-09-13 | 2006-03-16 | Mcburnett Doyle H | Method of medical modeling |
US20100324692A1 (en) * | 2007-04-17 | 2010-12-23 | Biomet Manufacturing Corp. | Method and Apparatus for Manufacturing an Implant |
US8473305B2 (en) * | 2007-04-17 | 2013-06-25 | Biomet Manufacturing Corp. | Method and apparatus for manufacturing an implant |
US20100013650A1 (en) * | 2008-07-18 | 2010-01-21 | Hon Hai Precision Industry Co., Ltd. | Shake responsive media player |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10716676B2 (en) | 2008-06-20 | 2020-07-21 | Tornier Sas | Method for modeling a glenoid surface of a scapula, apparatus for implanting a glenoid component of a shoulder prosthesis, and method for producing such a component |
US11432930B2 (en) | 2008-06-20 | 2022-09-06 | Tornier Sas | Method for modeling a glenoid surface of a scapula, apparatus for implanting a glenoid component of a shoulder prosthesis, and method for producing such a component |
US10314942B2 (en) * | 2014-06-30 | 2019-06-11 | Bacterin International, Inc. | Manufacture of biomaterial implants via three-dimensional printing technology |
US20150374450A1 (en) * | 2014-06-30 | 2015-12-31 | Bacterin International, Inc. | Manufacture of biomaterial implants via three-dimensional printing technology |
US10589465B2 (en) * | 2014-08-13 | 2020-03-17 | Lg Electronics Inc. | Terminal apparatus, system comprising terminal apparatus, and method for controlling terminal apparatus |
US10238507B2 (en) | 2015-01-12 | 2019-03-26 | Surgentec, Llc | Bone graft delivery system and method for using same |
US11116646B2 (en) | 2015-01-12 | 2021-09-14 | Surgentec, Llc | Bone graft delivery system and method for using same |
US11589960B2 (en) * | 2015-07-13 | 2023-02-28 | Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) | Customized alveolar bone tissue and method of forming the same |
WO2017010811A1 (en) * | 2015-07-13 | 2017-01-19 | 한양대학교 산학협력단 | Personalized alveolar bone tissue and method for manufacturing same |
US10814369B2 (en) | 2015-08-07 | 2020-10-27 | Arconic Technologies Llc | Architectural manufactures, apparatus and methods using additive manufacturing techniques |
US10442182B2 (en) | 2015-11-24 | 2019-10-15 | The Texas A&M University System | In vivo live 3D printing of regenerative bone healing scaffolds for rapid fracture healing |
US11642849B2 (en) | 2015-11-24 | 2023-05-09 | The Texas A&M University System | In vivo live 3D printing of regenerative bone healing scaffolds for rapid fracture healing |
US11065016B2 (en) | 2015-12-16 | 2021-07-20 | Howmedica Osteonics Corp. | Patient specific instruments and methods for joint prosthesis |
US20170273795A1 (en) * | 2016-03-25 | 2017-09-28 | Tornier Sas | Bone graft shaper & patient specific bone graft |
WO2017173333A3 (en) * | 2016-03-31 | 2017-11-09 | Lee Ernesto A | Method, devices and articles for conducting subperiosteal minimally invasive aesthetic jaw bone grafting augmentation |
US10327870B2 (en) | 2016-03-31 | 2019-06-25 | Ernesto A. Lee | Method, devices and articles for conducting subperiosteal minimally invasive aesthetic jaw bone grafting augmentation |
US10555794B2 (en) | 2016-03-31 | 2020-02-11 | Ernesto A. Lee | Devices for conducting subperiosteal minimally invasive aesthetic jaw bone grafting augmentation and their use |
TWI720175B (en) * | 2016-04-12 | 2021-03-01 | 德商贏創運營有限公司 | Method of producing three-dimensional objects from a powder bed by means of a binder jetting |
US10695978B2 (en) | 2016-04-12 | 2020-06-30 | Evonik Operations Gmbh | Spray-dried soft-phase emulsion polymer for filling the gussets in bead polymer layers in a binder jetting method |
US10793731B2 (en) | 2016-04-20 | 2020-10-06 | Evonik Operations Gmbh | Bead polymer made of hard phase with domains of a soft phase |
US10688718B2 (en) | 2016-09-28 | 2020-06-23 | Evonik Operations Gmbh | Production and use of porous bead polymers in 3D printing using the binder jetting method |
WO2018059912A1 (en) * | 2016-09-28 | 2018-04-05 | Evonik Röhm Gmbh | Production and use of porous bead polymers in 3d printing using the binder jetting method |
CN109790410A (en) * | 2016-09-28 | 2019-05-21 | 赢创罗姆有限公司 | Production and use of the porous beads polymer in the 3D printing using binder injection method |
USD950059S1 (en) | 2017-03-31 | 2022-04-26 | Ernesto A. Lee | Subperiosteal surgical instrument |
US10441426B2 (en) | 2017-04-18 | 2019-10-15 | Warsaw Orthopedic, Inc. | 3D printing of mesh implants for bone delivery |
US10064726B1 (en) | 2017-04-18 | 2018-09-04 | Warsaw Orthopedic, Inc. | 3D printing of mesh implants for bone delivery |
US11660196B2 (en) | 2017-04-21 | 2023-05-30 | Warsaw Orthopedic, Inc. | 3-D printing of bone grafts |
US11039871B2 (en) | 2017-06-23 | 2021-06-22 | Ernesto A. Lee | Subperiosteal syringe device for admitting bone graft material into a subperiosteal locus |
US10959742B2 (en) | 2017-07-11 | 2021-03-30 | Tornier, Inc. | Patient specific humeral cutting guides |
US11918239B2 (en) | 2017-07-11 | 2024-03-05 | Howmedica Osteonics Corp. | Guides and instruments for improving accuracy of glenoid implant placement |
US11076873B2 (en) | 2017-07-11 | 2021-08-03 | Howmedica Osteonics Corp. | Patient specific humeral cutting guides |
US11399851B2 (en) | 2017-07-11 | 2022-08-02 | Howmedica Osteonics Corp. | Guides and instruments for improving accuracy of glenoid implant placement |
US11166733B2 (en) | 2017-07-11 | 2021-11-09 | Howmedica Osteonics Corp. | Guides and instruments for improving accuracy of glenoid implant placement |
US11278299B2 (en) | 2017-07-11 | 2022-03-22 | Howmedica Osteonics Corp | Guides and instruments for improving accuracy of glenoid implant placement |
US11234721B2 (en) | 2017-07-11 | 2022-02-01 | Howmedica Osteonics Corp. | Guides and instruments for improving accuracy of glenoid implant placement |
US11293259B2 (en) | 2017-12-05 | 2022-04-05 | Saudi Arabian Oil Company | Additive manufacture of wellbore tubulars |
US10961813B2 (en) | 2017-12-05 | 2021-03-30 | Saudi Arabian Oil Company | Wellbore casing liner printing |
US11851978B2 (en) | 2017-12-05 | 2023-12-26 | Saudi Arabian Oil Company | Additive manufacture of casing liner in a wellbore |
US11293257B2 (en) | 2017-12-05 | 2022-04-05 | Saudi Arabian Oil Company | Additive manufacture of casing liner in a wellbore |
US11851979B2 (en) | 2017-12-05 | 2023-12-26 | Saudi Arabian Oil Company | Additive manufacture of wellbore tubulars |
US11293258B2 (en) | 2017-12-05 | 2022-04-05 | Saudi Arabian Oil Company | Additive manufacture of wellbore lining |
US11692413B2 (en) | 2017-12-05 | 2023-07-04 | Saudi Arabian Oil Company | Additive manufacture of wellbore lining |
CN112188952A (en) * | 2018-03-21 | 2021-01-05 | 埃森提姆公司 | High-speed extrusion 3-D printing system |
US10687828B2 (en) | 2018-04-13 | 2020-06-23 | Surgentec, Llc | Bone graft delivery system and method for using same |
US11116647B2 (en) | 2018-04-13 | 2021-09-14 | Surgentec, Llc | Bone graft delivery system and method for using same |
CN108765554A (en) * | 2018-05-21 | 2018-11-06 | 四川大学 | Heterogeneous core three-dimensional rebuilding method based on super dimension |
US11364323B2 (en) | 2018-09-17 | 2022-06-21 | Rejuvablast LLC | Combination grafts for tissue repair or regeneration applications |
WO2021016288A1 (en) | 2019-07-25 | 2021-01-28 | D2 Medical Llc | Bone-derived thermoplastic filament and method of manufacture |
US20210106723A1 (en) * | 2019-10-11 | 2021-04-15 | Advanced Solutions Life Sciences, Llc | Bone graft and methods of fabrication and use |
US11890396B2 (en) * | 2019-10-11 | 2024-02-06 | Advanced Solutions Life Sciences, Llc | Bone graft and methods of fabrication and use |
KR20210065694A (en) * | 2019-11-27 | 2021-06-04 | 울산과학기술원 | A method for manufacturing artificial cornea |
KR102304034B1 (en) | 2019-11-27 | 2021-09-17 | 울산과학기술원 | A method for manufacturing artificial cornea |
WO2021214515A1 (en) * | 2020-04-20 | 2021-10-28 | Mandelli Federico | Insert and procedure for bone regeneration |
IT202100019154A1 (en) * | 2021-07-20 | 2023-01-20 | Tsq Global S R L | DEVICE FOR OSTEOSYNTHESIS |
Also Published As
Publication number | Publication date |
---|---|
US11556682B2 (en) | 2023-01-17 |
US20190251217A1 (en) | 2019-08-15 |
US20200167514A1 (en) | 2020-05-28 |
US10579755B2 (en) | 2020-03-03 |
US20170024501A1 (en) | 2017-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10579755B2 (en) | Method for 3-D printing a custom bone graft | |
Vidal et al. | Reconstruction of large skeletal defects: current clinical therapeutic strategies and future directions using 3D printing | |
Sumida et al. | Custom-made titanium devices as membranes for bone augmentation in implant treatment: clinical application and the comparison with conventional titanium mesh | |
US5370692A (en) | Rapid, customized bone prosthesis | |
CA2630077C (en) | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix | |
Igawa et al. | Tailor-made tricalcium phosphate bone implant directly fabricated by a three-dimensional ink-jet printer | |
Eppley et al. | Cranial reconstruction with computer-generated hard-tissue replacement patient-matched implants: indications, surgical technique, and long-term follow-up | |
JP4504418B2 (en) | Method of manufacturing bioactive prosthetic device for bone tissue regeneration and prosthetic device | |
Mangano et al. | Custom-made computer-aided-design/computer-aided-manufacturing biphasic calcium-phosphate scaffold for augmentation of an atrophic mandibular anterior ridge | |
Mangano et al. | Maxillary ridge augmentation with custom-made CAD/CAM scaffolds. A 1-year prospective study on 10 patients | |
Bartnikowski et al. | Workflow for highly porous resorbable custom 3D printed scaffolds using medical grade polymer for large volume alveolar bone regeneration | |
Huang et al. | Main applications and recent research progresses of additive manufacturing in dentistry | |
Chang et al. | Regeneration of critical‐sized mandibular defect using a 3D‐printed hydroxyapatite‐based scaffold: An exploratory study | |
Calvo‐Guirado et al. | Retracted: Influence of Biphasic β‐TCP with and without the use of collagen membranes on bone healing of surgically critical size defects. A radiological, histological, and histomorphometric study | |
Helal et al. | Osteogenesis ability of CAD-CAM biodegradable polylactic acid scaffolds for reconstruction of jaw defects | |
Budharaju et al. | Ceramic materials for 3D printing of biomimetic bone scaffolds–current state–of–the–art & future perspectives | |
Crist et al. | Biomaterials in craniomaxillofacial reconstruction: past, present, and future | |
Thygesen et al. | Comparison of off-the-shelf β-tricalcium phosphate implants with novel resorbable 3D printed implants in mandible ramus of pigs | |
Dairaghi et al. | A dual osteoconductive-osteoprotective implantable device for vertical alveolar ridge augmentation | |
Kouhi et al. | Recent advances in additive manufacturing of patient-specific devices for dental and maxillofacial rehabilitation | |
GB2559945A (en) | Artificial bone composite | |
Hutmacher et al. | Craniofacial bone tissue engineering using medical imaging, computational modeling, rapid prototyping, bioresorbable scaffolds and bone marrow aspirates | |
Lozada et al. | 3D Printing and Bioprinting Technology for Specific Applications in Surgical Implant Dentistry: A Review | |
CH714037B1 (en) | Process for the production of an individual biomaterial shell for the reconstruction of bone defects. | |
Kargozar et al. | Scaffolds for the repair of orbital wall defects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |